

ält et algreen14

Kidney disease & Transplantations in Denmark

Emilie Nordby Lauritzen & Simon Kjær Bjerg

20. April 2017

Abstract

Contents

1	Introduction	5
1.1	Background	5
1.2	Purpose	5
1.3	Limitations & assumptions	6
2	Theory and Method	6
2.1	Cost Effectiveness Models	6
2.2	Markov Chain model	10
3	Costs	14
3.1	Direct Costs	14
3.2	Indirect Costs	15
4	Effectiveness	18
5	Tabeller	19

1 Introduction

1.1 Background

Living with a kidney disease is a life changing diagnosis that XXX live with in Denmark every year. Even with modern medicine the only cure for kidney disease is receiving a new organ. This reality means that there is a tremendous demand for donor kidneys, a demand that by far is exceeding the supply. Every year XXX dies while on a waiting list for a new kidney.

A lot of papers argue that the current Danish kidney program is inefficient reference and that the amount of donor kidneys could be increased by implementing a donor system. If Denmark were to actually implement a donor kidney system, it would be based on the premise, that kidney transplantations is favored in a socio-economic perspective relative to the patients with a kidney disease just getting dialysis. Based on this argument the paper seeks to perform a Cost Utility Analysis on kidney transplants weighted against the alternative, dialysis.

1.2 Purpose

The purpose of this paper is to analyse and compare the possible means of treatment, for individuals living with a kidney disease. The paper aims to illuminate the cost and benefits associated with the distinct treatment interventions, specifically comparing dialysis with transplantation.

To make this comparison, the paper seeks to uncover the price of dialysis and kidney transplantations and on that basis estimate the cost of both interventions. Furthermore we seek to approximate the before mentioned costs, in both a societal and regional perspective. Moreover we will investigate the effect of treatment in a Quality Adjusted Life Year framework, to better understand the associated effects in addition to merely considering the costs.

1.3 Limitations & assumptions

The focus of this paper is entirely be placed upon comparing the two current treatments for kidney disease - transplantation and dialysis. The analysis is based on aggregated data and simulations as data on the micro level hasn't been available.

As all modelling presented in this analysis is carried out based on aggregated data, it is plausible that some micro effects are missed. Only having aggregated data available implies that the accrued simulations are based on the *average* individual living with a kidney disease. This assumption *could* potentially mean that the analysis is missing important insights to the structural side of the cost and benefits related to the interventions.

Furthermore the paper assumes a discrete time horizon, why all cost and benefits accrued on a periodical level, and evaluated at the end of each year.

2 Theory and Method

2.1 Cost Effectiveness Models

When evaluating if a health program should be implemented or not, three different methods are commonly used; Cost Benefit Analysis (CBA), Cost Effectiveness Analysis (CEA) and Cost Utility Analysis (CUA). The approach and conclusion of the three methods differ, which makes them useful for different kinds of analyses. An effectiveness analysis consists of two parts, the costs and the effects of the intervention. The way the costs are estimated will generally be the same for the three effectiveness analyses, while the measurement of the effect will differ depending on the approach used [2]. In the following we will outline the method for each of the effectiveness analysis above and from this deduct the method we will use in this paper.

The CBA is the least used effectiveness analysis of the three mentioned. A CBA will directly compare the monetary cost and benefit of one or more

interventions and will always be conducted from the societies perspective. The CBA makes it easy to compare interventions because it is measured in monetary values, further more the CBA rests on the assumption that an intervention should only be implemented if the extra effectiveness (benefit) exceeds the extra cost of the intervention. (Edlin, McCabe, Hulme, Hall, Wright; 2014)

A CEA relies on the assumption that the purpose of an effectiveness analysis should be to maximize what the decision maker would like to maximize. (Edlin, McCabe, Hulme, Hall, Wright; 2014) This means that a CEA only includes what the decision maker finds relevant, which additionally depends on the kind of decision maker, which could be society, public sector, health sector or something completely else. In contrast to a CBA, a CEA is measured in natural units such as Incremental Cost Utility Ratio, number of deaths avoided etc. It is worth to point out that the natural unit should be consistent, which means it cannot change depending on the individual or intervention looked at (Edlin, McCabe, Hulme, Hall, Wright; 2014). CUA is seen as a sophisticated version of CEA, because a CUA is utility based. This means the outcome of a CUA takes the patients health state into account opposed to a CEA.

QALY – Quality Adjusted Life Years


I. In health economics Quality Adjusted Life Years is a common measure of the effectiveness of a given medical intervention. QALY measures the burden of disease and ranges from 1 and below. A QALY of 1 indicates full quality of a lived year (a healthy year), whilst a QALY lower than one identifies a life year of lesser quality than that of a life year in perfect health. A QALY of 0 is assigned to the state of being dead, while a QALY lower than 0 indicates a state deemed to be worse than dead.

In a CUA we can use QALY to weigh the effectiveness of the intervention. Practically, this means that the interventions may give the same outcome in

terms of living years, but with QALY we can take into account how well the patients feel in these years. The picture below shows how different QALY and Life Years after a treatment can be depicted. The area below the different graphs will then be the actual healthy years lived by the patient for each treatment.

HVORDAN MÅLER MAN QALY???

Figure 1: Interpretation of QALY



Source: [3]


ICER

When comparing interventions, we would like to know how much better a intervention is against the next best alternative. This is done by using the Incremental cost effectiveness ratio (ICER). The ICER is calculated in the following way:

$$ICER = \frac{C_2 - C_1}{E_2 - E_1} = \frac{\Delta C}{\Delta E} \quad (1)$$

where C_2 is the cost of the intervention under investigation, E_2 is the effectiveness of the intervention under investigations, C_1 is the cost of the comparison, E_1 is the effectiveness of the comparison. When using a CUA our effectiveness will be in QALY's and the ICER will reflect the extra cost of one more QALY. This can be plotted in the figure below, where the South Eastern quadrant is seen as dominant, and the intervention of interest should be implemented.

Figure 2: Plotting of ICER



Source: [3]

If results are plotted in the North Western Quadrant, then the alternative intervention will be dominant (the intervention of interest are both more expensive and less effective than the alternative). The last two quadrants (North East and South West) are a little more complicated, and in this case, the decision maker would set a ceiling ratio, which is the level of ICER which the intervention must meet to be cost effective and thereby implemented. This ceiling is sometimes seen as a willingness to pay, i.e. the willingness to pay an extra QALY.

In this paper, we investigate whether kidney transplantation is cost effective.

tive against the alternative, dialysis. As we want to take the quality of the patient's life into account, we will choose to use a CUA, to compare the two treatments.

2.2 Markov Chain model


The foundation for the Cost Utility Analysis is a Markov Chain model. A Markov Chain is a simple, yet powerful model, which is frequently applied in health economics. The Markov Chain model is used to explore the journey a hypothetical cohort of people can take through a defined set of states. The journey of a person in the Markov Chain model is based on the probabilities of switching between these states.

A Markov Chain is built on the idea that individuals can change between different states, which is defined as Markov states. In our model a Markov State is a specific health state. For any given point in time the individuals in the cohort have to appear in a Markov State, thus there cannot be individuals outside the defined states. Furthermore, the states are required to be mutually exclusive with no overlap allowed. An individual stays in a given health state for a fixed amount of time, a cycle. A cycle can be of any length and covers all the health states, why a cycle is of the same length for every state. At the end of every cycle the hypothetical individual either stays in their current health state or transitions to another.

A simple Markov Chain model consisting of 3 health states; Well, disease and dead. A graphic of this simple Markov Chain model can be examined in the influence diagram below.

The arrows in the diagram above identify the possible transitions between states. It is both possible to transition from well to disease and from disease to well, but once an individual has transitioned to dead, the individual is

Figure 3: Simple Markov model



Source

said to have reached an absorbing state. An absorbing state is defined by a 100% probability of staying in that state and therefore a 0% probability of transitioning to another state.

The Markov States are tied together through a transition matrix which defines the conditional probability of moving from one Markov State to another, or staying in the current state, conditioned on the current state. The transition matrix is applied at the end of every cycle. The cycles continue for a fixed amount of time or until a specific level of convergence is met. Below the framework for the above illustrated Markov Chain model can be examined.

Figure 4: Transition matrix

		End of period t (start of period $t+1$)		
		Well	Disease	Dead
Start of period t	Well	$P(\text{Well}_{t+1} \text{Well}_t)$	$P(\text{Disease}_{t+1} \text{Well}_t)$	$P(\text{Dead}_{t+1} \text{Well}_t)$
	Disease	$P(\text{Well}_{t+1} \text{Disease}_t)$	$P(\text{Disease}_{t+1} \text{Disease}_t)$	$P(\text{Dead}_{t+1} \text{Disease}_t)$
	Dead	$P(\text{Well}_{t+1} \text{Dead}_t)$	$P(\text{Disease}_{t+1} \text{Dead}_t)$	$P(\text{Dead}_{t+1} \text{Dead}_t)$

Markov Trace

Mathematically the Markov Chain model works through matrix multiplication where the cohort is multiplied with the transition matrix for each period in the model. This mathematical framework has the implication of making the model memory free. The memory free model is a simplification which makes the math easier and requires less of the underlying data. The simplification means that the hypothetical cohort is presented with the same transition matrix each period regardless of the previous states, thus the transition probabilities are merely conditional on the current health state, not prior health states.

Initially the desired output of the model is what is known as the Markov Trace. The Markov Trace is the movement of the cohort between Markov States, throughout the timeline of the model. For every period of the model the amount of people in each state is calculated.

Prices

Once the Markov Trace has been calculated the movement of the hypothetical cohort is known. This information allows for the calculation of a given medical intervention's cost over a given timeframe. The amount of individuals in each state is simply multiplied with the cost associated with every state in a period. Once the price of every period has been calculated the total price for the timeframe of the model is apparent when summing the costs of the individual periods.

Time & Discounting

The Markov Chain model is heavily depended on time, as cycles is a core element of the model. This implication of time, means that cycle length and time horizon of the model potentially can have a great impact on the model output. The cycle length is determined by the minimum timeframe of a stage. This cycle length is chosen as all stages abide by the same time structure, meaning that all individuals will stay in a given stage for the full

length of a cycle. In theory the cycle length can be decided arbitrarily, however in practice the minimum length of a distinct event is often chosen as it makes the analytical work easier. Sometimes events are combined to make more sensible cycle lengths. A hospitalization can easily include a variety of interventions (check of vitals, a scanning etc.) for ease these would typically be grouped together under the label hospitalization to keep a simpler cycle structure.

Previously when discussing the Markov Trace, transition probabilities were of great importance. Analytically it is therefore very important to consider how these probabilities are calculated based on the chosen cycle length.

Once the cycle length has been determined based on sensible arguments, the time horizon of the model has to be determined. The time horizon determines the amount of periods or cycles the model is run for. The time horizon needs to be meaningful in relation to the analysis at hand, meaning that it needs to run long enough to capture both short term and long term effects of a given intervention. The typical time horizon for health analysis is the expected lifetime of the sample in question. Sometimes the time horizon will differ from the expected lifetime for a variety of reasons. One reason could be a preference from the decision maker and the receiver of the analysis. A governmental budget might be available on a two-year horizon, why the analysis might be required to run for the same timeframe.

Lastly in relation to time it is also beneficial to think about when a given cost and benefit is encountered. Therefore, it is the norm to implement a discount rate to establish a consistent measure of cost and benefits. A discount rate is typically chosen based on country standards for the specific analysis at hand.

3 Costs

The CUA will both include direct and indirect costs. The direct costs are the costs directly linked to the treatment, where the indirect costs consider for example lost labor, early retirement etc. Other papers have only looked at the direct costs [4], but this does not take all of the relevant costs into account, as an early retirement can be the difference between being a net contributor or net gainer when it comes to public benefits. We therefore extend the analysis to take the indirect costs into account as well.

3.1 Direct Costs

There are several costs linked to having a kidney disease. These costs are identified by using the Danish diagnose-related groups (DRG) tariffs and the Danish Ambulatory Groups System (DAGS) that represent the average public health-care cost for patient treatments and ambulatory visits [5]. All costs are in 2016 DKK prices so we can compare.

DNSL!!!!!!!

Dialysis Costs

In regards to dialysis, there are as mentioned two different kinds the patient can choose between, P-dialysis and hemodialysis. The split between patients receiving P-dialysis and hemodialysis is 21,1% and 78,9% respectively [9] (evt fodnote omkring hvordan, det er fundet). Hemodialysis performed on a hospital requires 3 treatments a week. If the Hemodialysis is performed at home, a check-up every second month is required [6].

P-dialysis are almost always performed at home (99% of the time [9]), and we will assume that all patients getting P-dialysis, are doing the treatment at home. P-dialysis gives the patients more freedom and the patient can basically decide for themselves how often they would like to perform the dialysis. Even though the procedure for P-dialysis can differ, the patient needs to go

to a check-up on the hospital every 6th week, furthermore there is a cost linked to training the patient to be able to carry out the dialysis at home [7].

iiiiiii Updated upstream

Tranplantation Costs

When receiving a kidney, the kidney will either come from a living og deceased donor. In Denmark the share of kidneys recieved from deceased donors are 57,5% whereas the share of kidneys received from a living donor is 42,5% [9]. A deceased donor is assumed to donate 3,3 organs, and the price of the kidney donation from a living donor is therefore divided by 3,3 to get the cost of getting a kidney from a deceased donor.

The biggest cost in relation to a kidney transplantation is the actual surgery. The surgery is divided into two types; a complicated and a normal kidney transplantation. The probability of undergoing a complicated surgery is 11%, whereas the probability of a normal surgery is 89% [8] [4]. After having a kidney transplantation, the patient should go to a check up 2-3 times a week in the preceding year after the operation. If there is no complications the patient can go to check-ups every other month the following years [6].

Another cost linked to a kidney transplant is if the transplantation is not successful which means the kidney either undergoes graft failure or gets rejected. The probability of rejection is 18,5% [6], while the probability of graft failure is 4,9% [9]. In the case of graft failure or rejection, the patient will have to get dialysis or another kidney [6].

3.2 Indirect Costs

Production Loss

Indirect costs include all costs that are not directly linked to the treatment. Indirect costs could be lost production due to early retirement, short or long term sickness, job loss, lowered working hours etc. In this paper we will look

at the production loss for individuals with a chronic kidney disease.

Friction Cost Method vs. Human Capital Method

There are two ways of calculating production loss when evaluating health care interventions; the Friction Cost Method and The Human Capital Method. The Human Capital Method looks at the production loss from the employees standpoint and the loss will be the full amount of time the employee cannot work. The friction cost approach on the other hand sees the cost from the employers stand point and there will only be a production loss until the employee is replaced [10].

The Human Capital method is the approach used most often [10], and will be the method we use in this paper. In an ideal world we would look at all the individuals with a kidney disease and match these individuals up with a healthy individual from the population. If this was possible, we would be able to detect exactly how these two* individuals differed in regards to production the time after the kidney disease were discovered/apparent, which would be the production loss. This would be the most exact way to carry out the analysis, but due to the relatively narrow scope of this paper, we have chosen an easier and more straight-forward approach.

To calculate the production loss with the Human Capital Method, we need to find the production loss due to early retirement, job loss and sickness leave until the retirement age. A simple method for this is to calculate the average wage in Denmark and multiply that with the unemployment for the two interventions respectively. The unemployment should be corrected for structural employment, which in Denmark is 4% [11].

To our knowledge, there are no studies in Denmark studying the employment of individuals with a chronic kidney disease. However Helanterä (2001) investigates the employment of patients currently receiving dialysis and patients having undergone a successful kidney transplant. As the labor market

in Denmark and Finland are very similar, we will use the results from this paper. This approach has further more been used in other Danish studies trying to estimate the same [12].

The results from Helanterä (2001) is shown in the table below. Here we can see that 19% of the patients receiving hemodialysis were employed, 31% of the patients receiving P-dialysis were employed and 40% of the patients that had undergone a successful kidney transplant were employed. This means that the employment rate of individuals with a new kidney is significantly higher than the employment rate of the individuals receiving dialysis.

TABLE FOR UNEMPLOYMENT

To include the cost for the society, we calculate the average wage a year for an individual in the Danish labor force, which is calculated as the following:

$$\frac{TotalWage}{LaborForce} = \frac{Totalwage}{Employed + GrossUnemployed} \quad (2)$$

The numbers in (2) can be found in the Danish Statistics database and we get the following average wage:

$$\frac{1.027.380.000.000}{2.759.409 + 1.226.646} = \frac{1.027.380.000.000}{2.882.055} = DKK356.475,15 \quad (3)$$

Source: numbers are found on <http://www.dst.dk/> in table AUL1, RAS300, ERHV1

LAV TIL 2016 tal!!!!!!

When getting a kidney transplant, you are supposed to be on sick leave for 3 months cite{Rigshospitalet}. During the sick leave you will be compensated with sickness benefits from the Danish Government (Syge dagpenge), which is 4.245 DKK per week and 114,73 per hour [13]. These sickness benefits received in the preceding three months of the surgery will be a part of the

indirect costs for the transplanted individual.

With the numbers from the analysis above, we can calculate the production loss due to dialysis and kidney transplants respectively. The results is found in Table XXX and shows that the production loss when getting hemodialysis is the biggest followed by the patients having gotte a kidney transplant recently. The reason for the production loss for recently transplanted patients being so high is the sick benefits, the patient will receive the preceding 3 months. After the first year og having a transplant, the transplanted group will have a significantly lower production loss compared to the three other groups.

4 Effectiveness

As explained previously, QALY can be used to measure the patients quality of life and weigh the effectiveness of a treatment. In Sweden, Sennfält 2002 makes a CUA comparing P-dialysis and Hemodialysis. In this study, they ask patients with a chronic kidney disease about their HRQoL (Health Related Quality of Life). We will in this paper use the results from Sennfält 2002 as we assume the patient population in Sweden and Denmark is comparable. Further more the same approach have been taken in other studies [4].

5 Tabeller

Type	Procedure	Cost	Freq.	Weight	Yrl. Price
HD	At hospital	1946.00	156.00	0.93	282325.68
HD	At home check up	21773.00	6.00	0.07	9144.66
HD	Change to peritoneal dialysis	13111.00	1.00	0.03	413.00
HD	Mortality	0.00	1.00	0.19	0.00
PD	At home	1695.00	156.00	1.00	264420.00
PD	Home check up	20484.00	8.67	1.00	177528.00
PD	Change to haemodialysis	16818.00	1.00	0.21	3521.69
PD	Mortality	0.00	1.00	0.16	0.00
Transplantation	Deceased donor	11034.11	1.00	0.63	6951.49344.6 10
Transplantation	Living donor	55896.60	1.00	0.3742	20681.743756.05
Transplantation	Transplantation, complicated	540685.00	1.00	0.11	59475.35
Transplantation	Transplantation, normal	257992.00	1.00	0.89	229612.88
Transplantation	Check-up	1382.00	12.75	1.00	17620.50
Transplantation	Payment by patient	-3955.00	1.00	1.00	-3955.00
Transplantation	Rejection	41509.00	1.00	0.18	7471.62
Transplantation	Graft Failure	41509.00	1.00	1.00	41509.00
Transplantation	Change to p-dialysis	13111.00	1.00	0.04	519.20
Transplantation	Change to h-aialysis	16818.00	1.00	0.17	2820.38
Transplantation	Mortality	0.00	1.00	0.03	0.00
Transplantation	(Sandimmun Neoral)	25.08	730.00	1.00	18308.40
Transplantation	(Cellcept)	23.26	730.00	1.00	16979.80
Transplantation	(Prednisolon)	2.99	730.00	1.00	2182.70
Transplantation	Indirekte omkostning	255438.55	1.00	1.00	255438.55
Transplanteret	Indirekte omkostning	200253.55	1.00	1.00	200253.55
HD	Indirekte omkostning	276441.49	1.00	1.00	276441.49
PD	Indirekte omkostning	231238.03	1.00	1.00	231238.030
Dead	Indirekte omkostning	356475.15	1.00	1.00	356475.15

References

- [1] Metodebog
- [2] Christiansen; 2010
- [3] CUA bog
- [4] In dk
- [5] Takstvejledning 2016
- [6] Rigshospitalet om nyre
- [7] P-dialyse
- [8] Esundhed
- [9] DNSL
- [10] Friktion vs humankapital Van den Hout, W. B. "The value of productivity: human-capital versus friction-cost method." *Annals of the rheumatic diseases* 69.Suppl 1 (2010): i89-i91.
- [11] Strukturledighed på 4
- [12] Erikas speciale
- [13] Sygedagpenge (Borger.dk)
- [14] Qaly resultater